HOME AGENDA SPONSORS REGISTRATION CONTACT US

 

Overall Program Learning Objectives:
  1. Recognize the risks and benefits and implement strategies for managing patients with complex cardiovascular disease (CVD) including patients with atrial fibrillation (AF), hypertension, diabetes, chronic kidney disease and heart failure
  2. Identify co-morbid conditions and their impact on the development of cardiovascular disease (CVD)
  3. Translate evidence-based strategies for prevention, screening and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice

Learning Objectives: Session 1

  1. Identify individuals at elevated risk for atherosclerotic cardiovascular disease (ASCVD)
  2. Recognize the risks and benefits of coronary revascularization, including percutaneous coronary intervention (PCI), in patients with chronic coronary syndromes (CCS)
  3. Identify evidence-based lipid lowering management in patients with ASCVD
  4. Review the evidence-based, guideline-recommended secondary prevention treatment of patients with ASCVD, focusing on the post-acute coronary syndrome (ACS) transition to CCS management

Learning Objectives: Session 2

  1. Identify evidence-based management of patients with Heart Failure with reduced and non-reduced Ejection Fraction (HFrEF and HFnrEF)
  2. Review the role of evidence-based therapies in patients with ASCVD and co-morbid conditions including renal dysfunction, metabolic syndrome and diabetes
  3. Identify evidence-based management of patients who are obese/overweight

Learning Objectives: Session 3

  1. Review the role of evidence-based therapies in patients with hypertension, including frail and/or elderly individuals
  2. Review the screening for the diagnosis and management of atrial fibrillation (AF), including the role for AF ablation vs. pharmaceutical treatment
  3. Identify the role of oral anticoagulation therapy for stroke prevention in patients with AF who have concomitant coronary artery disease (CAD)

Learning Objective: Workshop 1

  1. Review and interpret challenging electrocardiograms

Learning Objective: Workshop 2

  1. Review, interpret and discuss the management of challenging vascular heart disease cases

 

  


Cardiology for the Practitioner
Hybrid Meeting
Saturday, April 11, 2026

 

AGENDA
 7:30 am Registration & Continental Breakfast  
8:30 Welcome and Introduction   Kim Connelly, MD
Session I: Coronary Artery Disease
Chair: Howard Leong-Poi, MD
  8:40 Detection of ASCVD before symptoms: Stress test, CTA, vascular US or microalbuminuria?
Interactive Learnig:5 min Q & A by use of on-line polling		 Yin Ge, MD
   
8:55 Should PCI be offered based on symptoms or narrowing?
Interactive Learnig:5 min Q & A by use of on-line polling		 John Graham, MD
   
9:10 Do current guidelines in lipid lowering reflect all the choices?
Interactive Learnig:5 min Q & A by use of on-line polling		 Beth Abramson, MD
   
9:25 Pathways to secondary prevention of ASCVD
Interactive Learnig:5 min Q & A by use of on-line polling		 Shaun Goodman, MD
   
9:40 Interactive Learning: Panel Discussion with audience, moderated session, Q&A augmented by use of on-line chat, Q&A or raising of hand Faculty
   
10:10 BREAK  
Session II: Heart Failure and Cardio-renal-metabolic
Chair: Chi-Ming Chow, MD
10:30 What is the minimal optimal therapy in HFrEF?
Interactive Learnig:5 min Q & A by use of on-line polling		 Stephanie Poon, MD
   
10:45 What is the minimal optimal therapy in HFnrEF?
Interactive Learnig:5 min Q & A by use of on-line polling		 Gordon Moe, MD
   
11:00 Cardio-renal-metabolic update
Interactive Learnig:5 min Q & A by use of on-line polling		 Kim Connelly, MD
   
11:15 Obesity/Overweight update
Interactive Learnig:5 min Q & A by use of on-line polling		 Sean Wharton, MD
   
11:30 Interactive Learning: Panel Discussion with audience, moderated session, Q&A augmented by use of on-line chat, Q&A or raising of hand Faculty
12:00 pm LUNCH  
Session III: Hypertension and Atrial Fibrillation
Chair: Victoria Korley, MD
12:45 Challenges in Hypertension Management
Interactive Learnig:5 min Q & A by use of on-line polling		 Philip McFarlane, MD
   
1:00 State of the art in Atrial Fibrillation update: Screening, diagnosis, ablation, rhythm or rate control?
Interactive Learnig:5 min Q & A by use of on-line polling		 Kaja Konieczny, MD
   
1:15 Antithrombotic management in patients with CAD and AF
Interactive Learnig:5 min Q & A by use of on-line polling		 Akshay Bagai, MD
1:30

Interactive Learning: Panel Discussion with audience, moderated session, Q&A augmented by use of on-line chat, Q&A or raising of hand

 Faculty
2:00 pm Didactic Session Close  
 2:15 pm Workshops In-Person Participants Only) – 30 minutes each  
  Workshop #1: Challenging ECGs - Read with an expert Iqwal Mangat, MD
  Workshop #2: Challenging Valve Cases - A heart team approach Tasnim Vira, MD
 2:45 pm Program Close  
     
Total Learning Time: 255 Minutes Total Learning Time with Workshop: 285 minutes
Total Interactive Learning: 145 Minutes Total Interactive Learning with Workshop: 175 minutes